<DOC>
	<DOCNO>NCT02346721</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy sofosbuvir ( SOF ) /velpatasvir ( VEL ; GS-5816 ) fixed-dose combination ( FDC ) administer 12 week participant chronic genotype 1 , 2 , 4 , 6 indeterminate HCV infection previously participate Gilead-sponsored study GS-US-342-1138 .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy Was administer placebo match SOF/VEL Gilead study GSUS3421138 HCV RNA ≥ 10^4 IU/mL screen Classification treatment naive treatment experience Males female childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Current prior history clinicallysignificant illness ( HCV ) major medical disorder may interfere treatment , assessment , compliance protocol ; individual currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude . Screening electrocardiogram ( ECG ) clinically significant abnormality Laboratory result outside acceptable range screen Prior exposure SOF nucleotide analogue HCV NS5B inhibitor HCV NS5A inhibitor Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>SOF/GS-5816</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>